Can-Fite BioPharma Ltd. (TLV:CANF)
1.900
0.00 (0.00%)
Apr 1, 2025, 4:45 PM IDT
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $158.00K USD in the quarter ending June 30, 2024, a decrease of -19.39%. This brings the company's revenue in the last twelve months to $667.00K, down -15.89% year-over-year. In the year 2023, Can-Fite BioPharma had annual revenue of $743.00K, down -8.27%.
Revenue (ttm)
$667.00K
Revenue Growth
-15.89%
P/S Ratio
12.02
Revenue / Employee
$83.38K
Employees
8
Market Cap
59.01M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teva Pharmaceutical Industries | 60.26B |
Danel (Adir Yeoshua) | 2.77B |
Kamada | 586.24M |
Bait Bakfar | 103.40M |
Novolog (Pharm-Up 1966) | 2.02B |
Ilex Medical | 982.96M |
BrainsWay | 149.39M |
SofWave Medical | 217.27M |
Can-Fite BioPharma News
- 12 days ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire
- 13 days ago - Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - GlobeNewsWire
- 4 weeks ago - Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewsWire
- 7 weeks ago - Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25 - GlobeNewsWire
- 7 weeks ago - Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025 - GlobeNewsWire
- 3 months ago - Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 5 months ago - Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial - GlobeNewsWire